Serina Therapeutics, Inc. (SER): M&A transaction — Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt

Serina Therapeutics, Inc.

Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.
Juvenescence is Serina's largest shareholder; Special Committee approved with third-party valuation.
UniverXome owned 94.8% of ReCyte and 100% of Reverse Bio, legacy AgeX assets from pre-merger.
Intellectual property transfer not perfected; buyer bears future filing costs.
Company makes no warranty beyond express representations; assets fully encumbered by pre-existing debt to buyer.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Serina Therapeutics, Inc. completed a disposition involving JuvVentures (UK) Limited for assumed approximately $11.2 million of secured debt (closed 2024-12-23).

Action: disposition
Counterparty: JuvVentures (UK) Limited
Consideration: assumed approximately $11.2 million of secured debt
Closing: 2024-12-23

Exact text from the filing

with the intent to revert aged or diseased cells to a healthy and functional state. As consideration for the purchase of UniverXome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to Juvenescence in addition to a nominal cash payment. The debt assumed by Juvenescence was secured by substantially all of the assets of

View on SEC.gov

30 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.